Skip to main content
. 2017 Dec 7;8(70):114506–114525. doi: 10.18632/oncotarget.23016

Figure 4. CAPE and CAPE-pNO2 inhibited inflammatory cytokines expression in diabetic mice.

Figure 4

(A, B) CAPE and CAPE-pNO2 treatment on MPO level in serum and kidney tissue. (C–F) The expressions of IL-6, tumor necrosis factor α (TNF-α) and interleukin-1β (IL-1β) were assessed by western blot analysis. (G, H) the immunohistochemical analysis of tumor necrosis factor α (TNF-α) activity in kidney sections. Data are expressed as mean ± SD, n ≥ 6. #p < 0.05 vs. control group; *p < 0.05 vs. diabetes group; +p < 0.05 vs. CAPE group; &p < 0.05 vs. Low-pNO2 group. Diabetes: the STZ-induced diabetic mice; CAPE: the STZ-induced diabetic mice treated with CAPE (20 μmol/kg/day); Low-pNO2: the STZ-induced diabetic mice treated with CAPE-pNO2 (20 μmol/kg/day); High-pNO2: the STZ-induced diabetic mice treated with CAPE-pNO2 (40 μmol/kg/day).